Morningstar

Akari Therapeutics PLC ADR AKTX

Stock XNAS Rating as of Nov 11, 2026

News

Akari Therapeutics Participates in Virtual Investor “What This Means” Segment Featuring Newly Appointed Chief Business Officer Vatnak Vat-Ho
GlobeNewswire Nov 11, 2026, 1:44:00 PM
Akari Therapeutics to Highlight Novel RNA-Splicing ADC Payload Strategy at the 3rd Annual ADC Payload Summit
GlobeNewswire Oct 30, 2026, 1:05:00 PM
Akari Therapeutics CEO Highlights Differentiated ADC Payload Strategy and Path Toward Clinical Development in New CEO Corner
GlobeNewswire Oct 15, 2026, 1:20:00 PM
Akari Therapeutics Appoints Accomplished Oncology and ADC Deal Executive Vatnak Vat-Ho as Chief Business Officer to Drive Strategic Growth and Partnering
GlobeNewswire Oct 13, 2026, 1:01:00 PM
Akari Therapeutics Expands Intellectual Property Portfolio with PCT Filing for ADC Payload Related to RNA Splicing in Cancers
GlobeNewswire Oct 1, 2026, 12:25:00 PM
Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums
GlobeNewswire Sep 8, 2026, 1:15:00 PM
Akari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
GlobeNewswire Aug 27, 2026, 1:01:00 PM
Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy
GlobeNewswire Aug 18, 2026, 12:53:00 PM

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

© Copyright 2026 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.